Search Results

You are looking at 41 - 47 of 47 items for :

  • "Interferon-α" x
  • Refine by Access: All x
Clear All
Full access

Pharmacotherapy for Chronic Myelogenous Leukemia: A Case-Based Approach

Stephen Harnicar

interferon-α (INF-α) significantly changed outcomes by providing a significant survival advantage over busulfan or hydroxyurea. 6 This drug was also able to produce a CyR, although at the cost of considerable toxicity. Because the BCR-ABL gene is

Full access

Basal Cell and Squamous Cell Skin Cancers

Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, Linda C. Wang, and John A. Zic

data supporting efficacy are limited. In the only phase II study of biochemotherapy with interferon-α, cis-retinoic acid, and cisplatin, 35 patients were assessed for response. Of these patients, 11 had distant metastases, 136 1 of whom experienced a

Full access

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Daniel G. Coit, John A. Thompson, Mark R. Albertini, Christopher Barker, William E. Carson III, Carlo Contreras, Gregory A. Daniels, Dominick DiMaio, Ryan C. Fields, Martin D. Fleming, Morganna Freeman, Anjela Galan, Brian Gastman, Valerie Guild, Douglas Johnson, Richard W. Joseph, Julie R. Lange, Sameer Nath, Anthony J. Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeffrey Sosman, Susan M. Swetter, Kenneth K. Tanabe, Evan Wuthrick, Nicole R. McMillian, and Anita M. Engh

staged by sentinel lymph node biopsy . J Clin Oncol 2016 ; 34 : 1079 – 1086 . 10.1200/JCO.2015.63.3776 15. Agarwala SS , Lee SJ , Yip W , . Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a

Full access

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Jerald P. Radich, Michael Deininger, Camille N. Abboud, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Lori Maness, Leland Metheny, Joseph O. Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg Purev, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory, and Hema Sundar

eventual outcome is poor . Blood 2008 ; 112 : 4437 – 4444 . 89. Hehlmann R Lauseker M Jung-Munkwitz S . Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia . J

Full access

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke, and Sandy Srinivas

-pathway targeting agents (temsirolimus and everolimus). Immunotherapeutic agents (interleukin-2 and interferon-α) are playing a much smaller role, and cytotoxic agents (e.g., gemcitabine and doxorubicin) are used on rare occasions. VHL mutation, HIF upregulation

Full access

Senior Adult Oncology

Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III, and Tanya Wildes

group compared with 7.3 and 8.4 months, respectively, in the groups treated with interferon-α alone or in combination with temsirolimus. Temsirolimus alone was associated with fewer incidences of grade 3 or 4 adverse events than interferon. Interferon is

Full access

Chronic Myelogenous Leukemia

Susan O'Brien, Camille N. Abboud, Mojtaba Akhtari, Jessica Altman, Ellin Berman, Daniel J. DeAngelo, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Vishnu V.B. Reddy, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Meir Wetzler, and Furhan Yunus

. J Clin Oncol 2010 ; 28 : 424 - 430 . 31 Hehlmann R Lauseker M Jung-Munkwitz S . Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia . J Clin Oncol 2011